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Abstract 
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a treatable chronic disorder of the peripheral nervous system. We 
retrospectively studied 30 children with a suspected diagnosis of CIDP. The diagnosis of CIDP was compared against the childhood CIDP 
revised diagnostic criteria 2000. Of the 30 children, five did not meet the criteria and four others met the criteria but subsequently had 
alternative diagnosis, leaving a total of 21 children (12 male) with CIDP as the final diagnosis. Thirteen children presented with chronic 
symptom-onset ( > 8 weeks). The majority presented with gait difficulties or pain in legs ( n = 16). 12 children (57%) met the neurophysiological 
criteria and 18/19 (94%) met the cerebrospinal fluid criteria. Nerve biopsy was suggestive in 3/9 (33%), with magnetic resonance imaging 
supportive in 9/20 (45%). Twenty-one children received immuno-modulatory treatment at first presentation, of which majority ( n = 19, 90%) 
received IVIG (immunoglobulin) monotherapy with 13 (68%) showing a good response. 8 children received second line treatment with either 
IVIG or steroids or plasmapharesis (PE) and 4 needed other immune-modulatory agents. During a median follow-up of 3.6 years, 9 (43%) 
had a monophasic course and 12 (57%) had a relapsing–remitting course. At last paediatric follow up 7 (33%) were off all treatment, 9 
(43%) left with no or minimal residual disability and 6 (28%) children were walking with assistance ( n = 3) or were non-ambulant ( n = 3). 
Our review highlights challenges in the diagnosis and management of paediatric CIDP. It also confirms that certain metabolic disorders may 
mimic CIDP. 
© 2018 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
Keywords: Inflammatory neuropathy; CIDP; Immuno-modulatory therapy. 
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(. Introduction 
Chronic inflammatory demyelinating polyradiculoneuropa- 
hy (CIDP) is an immune mediated treatable disorder of the
eripheral nerves, with predominant motor involvement and
n insidious onset over months, or recurrent episodes [1] .
hildren present with slowly progressive or relapsing episodes
f gait difficulty, distal symmetric weakness and sometimes
araesthesiae [2] . Reflexes are absent or depressed. Labora-
ory findings include elevated cerebrospinal fluid (CSF) pro-∗ Corresponding author. 
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960-8966/© 2018 The Authors. Published by Elsevier B.V. This is an open acce
 http://creativecommons.org/licenses/by/4.0/ ) ein with no increase in cells. Electrophysiological and patho-
ogical studies show evidence of demyelination. The diagnosis
f CIDP is usually straightforward, but atypical presentations
an represent a significant diagnostic challenge [3] . Differ-
ntial diagnoses include its acute counterpart, Guillain–Barré
yndrome (GBS), as well as hereditary and metabolic causes
f childhood polyneuropathy [2] . 
CIDP results in segmental and multifocal demyelination 
hat may induce axonal loss with time. Goals of diagnosis
nd management are to control the inflammation and there-
ore prevent axonal loss and the resulting disability. Although
n some the course is monophasic with complete recovery,
n others it can be slowly-progressive, or relapsing-remittingss article under the CC BY license. 
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s  resulting in prolonged morbidity and sometimes permanent
disability [1] . However, if diagnosed and treated promptly,
children with CIDP typically respond well to immuno-
modulatory therapy and the prognosis for remission of neu-
rologic deficits may be good. 
CIDP is less common in children than adults and hence
knowledge of the clinical characteristics, response to treat-
ment, and prognosis are often based on several small paedi-
atric series. In this series we attempt to describe the presenta-
tion, diagnosis, response to treatment and long-term outcome
of childhood CIDP. 
2. Methods 
Children seen in the neuromuscular service at a single ter-
tiary unit from 1992 to 2015 with a suspected diagnosis of
CIDP were identified from our neuromuscular and neurophys-
iology databases and their medical records were reviewed. 
Revised diagnostic criteria for childhood CIDP proposed
by Nevo et.al. [1] ( Table 1 ) were used to define criteria for
diagnosing children with CIDP. This was based on manda-
tory clinic criteria which includes two features (i) Progres-
sion of muscle weakness in proximal and distal muscles of
upper and lower extremities over at least 4 weeks, or alterna-
tively when rapid progression (GBS like presentation) is fol-
lowed by relapsing or protracted course (more than 1 year),
and (ii) Areflexia or hyporeflexia. Apart from the requirement
of mandatory clinical criteria; for confirmed CIDP diagnosis
specific electrodiagnostic (EDT) and CSF features were also
required, whereas 1 of 3 paraclinical findings (EDT, CSF or
biopsy features) was required for possible CIDP diagnosis. 
Published reference values for normal paediatric sensory
and motor nerve conduction values were used [4] . Evidence
for nerve root thickening and/or enhancement on magnetic
resonance imaging (MRI) of the lumbosacral spine was not
included as a part of the diagnostic criteria (as per 2000 cri-
teria). 
Information was obtained on age of onset, time to max-
imum disability, symptoms at presentation; disease course,
immuno-modulatory treatment used and disease activity at last
follow up. An attempt was made to identify atypical features
in the suspected CIDP cases that later had a diagnostic revi-
sion. Clinical deficit was quantified using the Modified Rankin
scale (MRS; Table 2 ) [2] at peak motor disability and last fol-
low up. Disease outcome at last follow up visit was assessed
using the CIDP Disease Activity Status (CDAS) scale [5] .
Disease relapse was defined as clinical deterioration not as-
sociated with weaning immunosuppressant medication and/or
wearing-off effects of IVIG or plasma exchange therapy and
clinical response to treatment was sub-classed as good, partial
and no response as defined by McMillan et.al. [2] . 
3. Results 
Thirty children with CIDP suspicion were identified
( Fig. 1 ) and their characteristics were compared with the re-ised diagnostic criteria for childhood CIDP 2000 proposed
y Nevo et al. [1] . All but five cases ( n = 25) met the criteria;
en met the confirmed CIDP criteria and 15 met the possible
IDP criteria. Five cases that did not meet the criteria had
 later diagnostic revision to GBS in four cases and a likely
enetic cause in the other. Amongst twenty-five that met the
riteria four subsequently had alternative diagnosis and were
xcluded. A total of 21 cases were established to have CIDP
nd these are detailed as below 
.1. Clinical presentation (Supplementary table S1) 
The mean age of onset was 7 years and 3 months; range
–16 years. Symptom onset was acute ( < 4 weeks) in five,
hree had a sub-acute (4–8 weeks) and more than 50% had a
hronic ( > 8 weeks) onset ( n = 13). Two children included in
he chronic group had leg pains and foot deformity for more
han a year and then became non-ambulant acutely. The inter-
al between symptom onset and maximum disability ranged
rom < 1–44 months. Preceding infectious illness was present
n less than half ( n = 11). 
The majority of children presented with gait difficulties
 n = 11); all subsequently developed 4 limb involvement. All
hildren were areflexic with one hyporeflexic at presentation.
/21 (14%) had bulbar weakness with weak cry or swallow-
ng/speech difficulty with two others having cranial nerve in-
olvement with anisocoria/optic neuritis and bilateral lower
acial weakness, respectively. 
.2. Investigations (Supplementary table S2) 
Electrophysiology studies done in all the twenty-one chil-
ren who met the CIDP diagnostic criteria were reviewed; of
hom 12 met the electrodiagnostic criteria for CIDP. Param-
ters that were looked into included presence or absence of
onduction block, sensory and motor nerve conduction veloc-
ties, distal CMAP latency and F wave latency. A minimum
f four to five nerve were studied. In these 12 children that
et the electrodiagnostic criteria for CIDP the study was de-
yelinating in majority ( n = 8), and both demyelinating and
xonal changes in four cases. 
Rest of the 9 cases that met the CIDP criteria (confirmed
r possible) did not meet all the required major or supportive
riteria to meet the electrodiagnostic criteria for CIDP; of
hese two had only axonal changes. 
Lumbar puncture was performed in all but 2 cases and
ajority ( n = 18/19; 94%) met the CSF criteria [1] . Two had
ow CSF protein ( < 0.35 g/l) and one with high CSF cell count
10 white cells). A diagnostic peripheral nerve biopsy ( Fig. 2 )
as performed in 9/21 cases. In 6/9 cases, there was unequiv-
cal evidence of demyelination; of which only three showed
 more typical CIDP pattern with patchy demyelination, in-
ammation and oedema. 
Genetic testing for inherited neuropathies was done in
alf of the cases ( n = 10) with pre-existing, early or progres-
ive foot deformity and/or poor response to treatment. These
A. Silwal et al. / Neuromuscular Disorders 28 (2018) 757–765 759 
Table 1 
Revised diagnostic criteria for childhood (2000)–CIDP. 
1. Confirmed CIDP 
(i) Mandatory clinical features. 
(ii) Electrodiagnostic and CSF features. 
2. Possible CIDP 
(i) Mandatory clinical features. 
(ii) One of the 3 laboratory findings 
Exclusion criteria 
1. Clinical features or history of a hereditary neuropathy, other diseases or exposure to drugs or toxins that are known to cause peripheral 
neuropathy. 
2. Laboratory findings (including nerve biopsy or DNA studies) that show evidence for a different etiology other than CIDP. 
3. Electrodiagnostic features of abnormal neuromuscular transmission, myopathy or anterior horn cell disease 
- Mandatory clinical criteria: 
• Progression of muscle weakness in proximal and distal muscles of upper and lower extremities over at least 4 weeks, or alternatively when 
rapid progression (GBS like presentation) is followed by relapsing or protracted course (more than 1 year). 
• Areflexia or hyporeflexia. 
- A.1. Major laboratory features: Electrophysiological criteria/CSF studies/N.biopsy 
A.1.1. Electrophysiological criteria 
Must demonstrate at least three of the following four major abnormalities in motor nerves (or 2 of the major plus 2 of the supportive criteria): 
A.1.1.1. Major 
1. Conduction block or abnormal temporal dispersion in one or more motor nerves at sites not prone to compression. 
a. Conduction block: at least 50% drop in negative peak area or peak-to-peak amplitude of proximal compound muscle action potential 
(CMAP) if duration of negative peak of proximal CMAP is < 130% of distal CMAP duration. 
b. Temporal dispersion: abnormal if duration of negative peak of proximal CMAP is > 130% of distal CMAP duration. 
Recommendations: (a) Conduction block and temporal dispersion can be assessed only in nerves where amplitude of distal CMAP is > 1 mV. (b) 
Supramaximal stimulation should always be used. 
2. Reduction in conduction velocity (CV) in two or more nerves: < 75% of the mean minus 2 standard deviations (SD) CV value for age. 
3. Prolonged distal latency (DL) in two or more nerves: > 130% of the mean 12 SD DL value for age. 
4. Absent F waves or prolonged F wave minimal latency (ML) in two or more nerves: > 130% of the mean 1 2SD F wave ML for age. 
5.Recommendation: F wave study should include a minimum of 10 trials. 
A.1.1.2. Supportive 
1. When conduction block is absent, the following abnormal electrophysiological parameters are indicative of non-uniform slowing and thus of 
an acquired neuropathy: 
2. Abnormal median sensory nerve action potential (SNAP) while the sural nerve SNAP is normal. 
3. Abnormal minimal latency index (TLI) [1] . 
4. Difference of > 10 m/s in motor CVs between nerves of upper or lower limbs (either different nerves from the same limb for example left 
median versus left ulnar or the same nerve from different sides for example left versus right ulnar nerves). 
A.1.2. Cerebrospinal fluid (CSF studies) 
• CSF protein > 35 mg/dl. 
• Cell count < 10 cells/mm3. 
A.1.3. Nerve biopsy features 
Nerve biopsy with predominant features of demyelination. 
Table 2 
Modified Rankin Score. 
1 mild symptoms that do not interfere with any work, school or extracurricular activity 
2 slight disability (i.e. child has given up one or more activities) but is able to perform all age-appropriate personal care (i.e. dressing, eating) and 
complex tasks (i.e. handwriting, age-appropriate food preparation); 
3 moderate symptoms (i.e. child is still able to walk independently (may require cane or walker) but requires assistance for age-appropriate tasks 
(see above)) 
4 moderate-to-severe symptoms (i.e. child is unable to walk (carried by parent and/or wheelchair required) and unable to perform age appropriate 
personal care) 
5 severe disability (i.e. patient is bed-ridden and requires constant nursing care), may require intubation and mechanical ventilation 
6 Death 
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ancluded comprehensive 56 gene inherited neuropathy panel
INP) in three and were negative in all cases. 
Neuroimaging of spine was done in 20 and 9 (45%)
ad thickening and/or enhancement of cauda equina nerve
oot ( Fig. 3 ). Two others had incidental thoracic syrinx and
egenerative disc changes respectively. Brain imaging waserformed in 14 and all were reported as normal except 1 with
ilateral 3, 5, 7 and 8 cranial nerve enhancement. Clinically
his cranial nerve involvement manifested as facial and bulbar
eakness with speech and swallow difficulties and optic neu-
itis and all these symptoms responded to immunoglobulins
nd steroids therapy. 
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Fig. 1. Comparison of CIDP cases with revised CIDP 2000 criteria. GBS: Guillain–Barré syndrome, MNGIE: Mitochondrial Neurogastrointestinal Encephalopa- 
thy, MLD: Metachromatic Leukodystrophy 
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p  3.3. Treatment (Supplementary table S2, Fig. 4 ) 
All twenty-one children received immuno-modulatory
treatment as first line therapy, of which majority ( n = 19;
90%) received IVIG monotherapy with 68% ( n = 13/19)
showing a good response after first dose. IVIG was then
gradually weaned and eventually 6/13 (46%) children with
good response to IVIG were off treatment irrespective of dis-
ease course (monophasic or relapsing) over a mean FU of 5.5
years (range 1.1–13.7 years). 5 children had side effects in-
cluding headache, nausea, vomiting and transient high blood
pressure but continued on therapy. Two children were started
on steroids as first line with partial response in one and no
response in other. 
Eight children needed second line treatment which was
IVIG in two and steroids in six; of these one each in IVIG
group had a good or partial response whereas four in theFig. 2. Nerve biopsy image legend: Pathology from peripheral nerve biopsies
P27 at 11 years, 4 months (I-K) and P1 at 14 years (L-N). P3: Immunostaini
highlights mild endoneurial microglial activation, and labeling of occasional mye
from a resin semi-thin section stained with Toluidine blue (Ci), there are thinly m
myelinated axons. Note the absence of well-formed onion bulbs and regeneration c
paranodal/segmental demyelination. P7: A representative fascicle from a resin sem
nation affecting majority of axons that show inappropriately thin myelin sheaths
brown-staining storage material (arrows) within endoneurial cells, with striking gr
(E-H) shows hypomyelinated/demyelinated axonal profiles with myelin debris a
F). Higher magnification reveals ‘tuff stone’ (G) and ‘prismatic’ (H) inclusions c
scattered endoneurial cells and occasional endoneurial perivascular clusters (arro
oedematous fascicles of uniform appearance (J). Within each fascicle, there is pa
response with prominent, frequent onion bulbs (circles, K). P1: Immunostaining fo
inflammatory cells (L). Resin semi-thin sections stained with MBA-BF show ma
axonal loss and the surviving axons show a uniform pattern of hypomyelination 
100 μm; C, D, K, N = 10 μm teroid group had a good response to therapy. Those with
artial response went on to plasmapheresis in 2 and azathio-
rine in one case. 
43% ( n = 9) had a monophasic course and 57% ( n = 12)
ad a relapsing–remitting course. Of the 12/21 children with
elapsing-remitting course, three evolved to chronic progres-
ive. The majority had 2–5 relapses ( n = 6) and three children
ach had 1 or more than 5 relapses ( n = 3) with 3 weeks to
4 months interval between relapses. 
IVIG was trialed as first line therapy for relapse in the
ajority of cases ( n = 10) and prednisolone was used in
he other two. 4 children in this group continued with re-
apse or progression and were trialed on other immuno-
odulatory therapy including plasma exchange (PE), aza-
hioprine, cyclophosphamide and mycophenolate, none of
hem had a good response except PE in one. Cyclophos-
hamide was trialed in one child for ten courses with in P3 at 3 years, 10 months (A-Cii), P7 at 2 years, 6 months (D-G), 
ng for CD3 (A) shows virtually no inflammatory cells, whilst CD68 (B) 
lin ovoids indicating acute axonal degeneration. In a representative fascicle 
yelinated large and small diameter axons (arrows) admixed with normally 
lusters. A teased fibre preparation (Cii) shows a myelinated fibre undergoing 
i-thin section stained with Toluidine blue (D). There is uniform hypomyeli- 
. Onion bulbs are not prominent. There is accumulation of metachromatic 
een dichroism seen under polarised light (inset). Ultrastructural examination 
nd osmiphilic storage material within the cytoplasm of Schwann cells (E, 
haracteristic of sulfatide storage. P27: Immunostaining for CD3 shows few 
w, I). A Toluidine blue resin semi-thin stained section shows moderately 
tchy demyelination associated with a prominent hypertrophic Schwann cell 
r CD3 + shows one of several prominent clusters of endoneurial perivascular 
ssive endoneurial oedema across three fascicles (M). There is considerable 
surrounded by hypertrophic onion bulbs (N). Scale bar: A, B, I, J, L, M = 
A. Silwal et al. / Neuromuscular Disorders 28 (2018) 757–765 761 
Fig. 2. 
762 A. Silwal et al. / Neuromuscular Disorders 28 (2018) 757–765 
Fig. 3. 1a–c: Axial contrast enhanced T1-weighted MRI brain sections showing enhancing cranial nerves marked by arrows. 3rd cranial nerves (1a), left 
5th cranial nerve (1b) and left 7th and 8th nerves (1c). 1d-f: Axial and sagittal contrast T1-weighted MRI spine sections (d,e respectively) and sagittal 
T2-weighted MRI (f) shows thickened enhancing cauda equine roots. 
Fig. 4. Treatment flowchart. 
A. Silwal et al. / Neuromuscular Disorders 28 (2018) 757–765 763 
Fig. 5. Modified Rankin Score for the group showing more number of children with improved score at last follow up compared to higher number of children 
with worse scores during peak of illness. 
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t  inimal response and no motor worsening. Three children
emain on mycophenolate and IVIG infusions with minimal
esponse. 
Three children developed adverse effects with steroid use
ncluding osteoporosis, triplanar fracture of right ankle and
edge vertebral fracture in one and hypercalciuria and renal
alculi in two others; azathioprine caused deranged liver en-
ymes, lymphopenia and gastrointestinal symptoms in three
atients respectively and was stopped. 
Of the 21 children, at last follow up, 7 were off treatment,
3 on treatment and 1 child passed away at 14.8 years with
1N1 influenza while on treatment. 
.4. Outcome (Supplementary table S2) 
At last paediatric follow up 33% ( n = 7) were off all treat-
ent, of these, two were cured as per CDAS classification
stable and off treatment for more than 5 years) and 5 others
ere in remission (stable and off treatment for less than 5
ears). A total of six (28%) still had unstable active disease
nd were on treatment. 
On reviewing the MRS scores ( Fig. 5 ) 13 children had a
eak motor disability MRS of 4–5 and this number reduced
o 3 children with MRS 4–5 at last follow up (Supplementary
able S2). 43% ( n = 9) were left with no or minimal residual
isability. 
.5. Diagnostic revisions difficulties and atypical cases 
Supplementary Table S2 highlights the findings in indi-
idual cases that led to diagnostic revisions. These included
ndings like early onset, pre-existing wasting/contractures, 
ssociated co-morbidities like development delay, epilepsy, 
hromosomal deletions, cognitive decline and abnormal in-
estigations like high CK or abnormal metabolic profile, poor
r no response to IVIG therapy. Of the total 30 cases with initial suspicion of CIDP, 19
 Fig. 1 ) had a re-evaluation of diagnosis either to CIDP or an
lternate diagnosis due to new / atypical findings or investi-
ation results or change in disease course. In 10/19 (52.6%)
IDP was the final diagnosis and nine had alternative diag-
oses (MLD, MNGIE, mitochondrial, likely genetic neuropa-
hy ( n = 2) and GBS ( n = 4). The diagnosis of CIDP is thus
ery challenging and needs frequent re-evaluation. 
Two children in our cohort were later diagnosed with
NGIE and MLD respectively. Both these children met the
linical, CSF and electrophysiological criteria for demyeli-
ation and managed as CIDP initially. A routine screen for
rine organic acids was abnormal in one and led to a genetic
iagnosis of MNGIE two years after presentation. 
The other child with MLD presented with unsteady gait
nd loss of ambulation at 13 months and showed a partial
esponse to IVIG. Nerve biopsy showed presence of granu-
ar storage material in cytoplasm of myelinating schwann cell
nd was crucial in leading to the diagnosis of MLD. Mean-
hile, her symptoms progressed with cognitive decline and
pper motor neuron signs. Arylsulfatase A activity was very
ow in white blood cells, and the diagnosis was subsequently
enetically confirmed with compound heterozygous mutations
n the ARSA gene. MRI brain at 2.6 years showed typically
igroid pattern of leukodystrophy with bilateral dark thalami
ith thickening and enhancement of 3rd, 5th, 7th and 8th
ranial nerve and cauda equina nerve roots. 
Two siblings born to non-consanguineous parents were
hought to have a congenital onset of CIDP. History of poly-
ydramnios and reduced fetal movements suggested antena-
ally onset disorder. The index case was born following foetal
istress, needing CPAP support for two days. She was pro-
oundly hypotonic, weak with poor antigravity movements
nd areflexia. At four weeks of age her NCS demonstrated
bsent sensory nerve action potentials (NAP), motor con-
uctivity (cV) 1–2 m/s and dispersed compound motor ac-
ion potentials (CMAP). She was treated with 4–5 courses
764 A. Silwal et al. / Neuromuscular Disorders 28 (2018) 757–765 
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f  of IVIG following which she had gradual normalization of
clinical examination and NCS at 9.5 months of age. Her
younger sibling presented similarly with hypotonia and weak-
ness and responded well to IVIG therapy, continuing to
make improvement. Her mother when tested did not have a
neuropathy. 
Two children initially thought to have CIDP were later
considered to have a genetic etiology; one among them (Pt
8) presented at 4 years with only lower limb, distal involve-
ment with tip toe gait and thereafter rapidly progressive bi-
lateral equinovarus and calf wasting. Nerve biopsy showed
a chronic picture of re and demyelination with no active
inflammation, more suggestive of a genetic cause. The other
child (Pt 15) had an early presentation and developed a pro-
gressive disease course with marked foot deformity. A nerve
biopsy was declined. Both the children did not respond to
therapy with negative genetic testing including inherited neu-
ropathy panel. 
4. Discussion 
We are presenting data of CIDP cohort from a single
tertiary center in UK. McMillan et al have previously re-
ported on 30 American children with CIDP and combined
this with data from 11 previous case series (1980–2009) to
provide a comprehensive review of 143 childhood CIDP cases
[2] . 
Based on the revised diagnostic criteria for childhood
CIDP proposed by Nevo et al. [1] , all but 5 cases in our group
of 30 met the inclusion criteria. 4 others met the CIDP revised
criteria but had alternate diagnosis made and this highlights
the difficulty in establishing a CIDP diagnosis despite updated
criteria. The updated criteria rely on EDT criteria and 9 of
the 21 children did not meet these. While nerve studies can
present challenges in children and often less studies might be
performed compared to examination of a co-operative adult,
in this study at least 4 nerves were examined, if studied at
our centre. 
The overlap between GBS and acute onset CIDP and be-
tween inherited neuropathy and CIDP were the two main
common themes in differential diagnosis in our group. Dif-
ficulties in diagnosis of GBS and the acute onset CIDP is
known (Riekhoff et al. [6] ). Children with initial suspicion
of GBS ( n = 9) in our group had diagnostic revision due
to relapse, progression or pre-existing wasting or contrac-
tures. Due to the chronic nature of symptoms genetic neu-
ropathies can mimic CIDP and can be equally challenging to
differentiate the two. Shabo et al. [7] presented retrospec-
tive data on 118 children with polyneuropathies to obtain
an overview of their etiologies. Hereditary polyneuropathies
made up 68%. In our group, hereditary polyneuropathy was
raised as a differential diagnosis in 11 but not proven so
far. 
A clinical suspicion of CIDP along with appropriate tests,
treatment, regular follow up and serial electrodiagnostics
helped to confirm the diagnosis in our cohort. In cases wherehere were atypical features either in history, investigations or
rogression, the diagnosis was revised. This is shown by 52%
 n = 10/19) of our cohort diagnosed as CIDP on re-evaluation
uggesting the challenges in diagnosis of this treatable con-
ition. 
The diagnostic pathological differentiation between a ge-
etic versus acquired demyelinating neuropathy is equally
hallenging, as evidenced from our biopsy series. Three cases
ad a more confident diagnosis favouring CIDP showed the
lassic patchy demyelination with three others having a patho-
ogical diagnostic ambiguity on account of presence of over-
apping pathology between genetic neuropathy versus CIDP
r lack of a ‘full house’ e.g. lack of overt inflammation,
 more uniform pattern of demyelination and inconspicuous
nion bulbs. Biopsies were normal in two cases and showed
nly acute axonal degeneration in two; of these 2 had a di-
gnosis of CIDP. This highlights that lack of biopsy evidence
oes not exclude a demyelinating process. 
We had two established metabolic diagnosis (MNGIE and
LD), which were initially diagnosed as CIDP. This has been
eported in literature. Bedlack et al. [8] described five pa-
ients with genetically confirmed MNGIE neuropathy mim-
cking CIDP. They were initially diagnosed with CIDP, and
hree were treated with immunomodulating drugs with poor
esponse. Haberlandt et al. [9] reported on three children with
LD who presented with a demyelinating polyneuropathy in
he absence of white matter changes in brain MRI, which
an be challenging, as was our case with subtle MRI changes
arlier on. 
In our study the two siblings thought to have congeni-
al CIDP had a later diagnostic revision to GBS. Congen-
tal presentations of CIDP are rare but have been reported
efore [10,11] . Majumdar et al. [11] reported on a neonate
ith severe congenital CIDP with complete spontaneous res-
lution and hypothesised an intrauterine neuropathy due to ei-
her expression of foetal myelin antigen and/or antibody trans-
er between mother and foetus, raising a possibility of an im-
unologically driven injury to the myelin sheath in utero. In
ur case mother and baby’s blood have been sent for further
nalysis to investigate into antibody-mediated process against
he foetal myelin. 
Cranial nerve involvement has been reported in children
ith CIDP and can cause considerable diagnostic confusion.
e as clinicians need to be aware of this presenting feature
n CIDP. Costello et al. [12] reported on a 17 year old who
resented with chronic diplopia, facial weakness and general-
zed motor weakness and was diagnosed with CIDP. Review
rticle by Riekhoff et al. [6] highlights the eye signs, cranial
erve palsies and bulbar disturbances in children with CIDP
nd that cranial nerve involvement may be the only presenting
ymptom. 
In our study the treatment response to first line IVIG
herapy was deemed as good in 68% of cases; this is compa-
able to the existing literature with a combined value of 79%
rom 135 total reported cases by McMillan et al. [2] . IVIG
as well tolerated in our group. Steroid therapy was used in
ewer cases but relapse of CIDP symptoms after withdrawal
A. Silwal et al. / Neuromuscular Disorders 28 (2018) 757–765 765 
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 f therapy was a major problem. Only a few children were
rialed on other immune-modulatory agents and as the num-
ers were small it is difficult to draw conclusions from this
roup. 
McMillan et al. [2] . highlighted that the combined long
erm outcome for their cohort and the literature revealed a
avourable prognosis for most patients with childhood CIDP.
imilar data was also presented by Riekhoff et al. [6] . In
ur group there was an overall improvement in MRS ( Fig. 5 )
rom scores at peak motor disabilty) to scores at last follow
p There was no deterioration in MRS score in any child
uring the follow up period though in 2 children there was no
mprovement in scores despite treatment. In 5 children there
as no disability noted at follow up with complete recovery
nd this complete recovery in cases of childhood CIDP has
een seen in several case reports [6] . 
. Conclusion 
Our review highlights the challenges in the diagnosis and
anagement of paediatric CIDP. In general this is a rare di-
gnosis but clinical suspicion, early recognition and inves-
igation with prompt management can result in better out-
omes of this potentially treatable neuropathy. Our review also
ighlights that various differential diagnoses must be consid-
red in cases where the disease course changes or new signs
volve. 
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